text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 162011-90-7 | Product Number: R0206

Rofecoxib


Purity: >98.0%(GC)
Synonyms:
  • 4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone
Product Documents:
250MG
55,00 €
1   15  
1G
166,00 €
1   25  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number R0206
Purity / Analysis Method >98.0%(GC)
Molecular Formula / Molecular Weight C__1__7H__1__4O__4S = 314.36 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
Packaging and Container 250MG-Glass Bottle with Plastic Insert (View image)
CAS RN 162011-90-7
Reaxys Registry Number 8269007
PubChem Substance ID 354335586
Merck Index (14) 8248
MDL Number

MFCD00935806

Specifications
Appearance White to Yellow to Orange powder to crystal
Purity(GC) min. 98.0 %
Melting point 207.0 to 211.0 °C
NMR confirm to structure
Properties (reference)
Melting Point 209 °C
Solubility in water Insoluble
Degree of solubility in water 472 mg/l   25 °C
Solubility (slightly sol. in) Methanol
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H302 : Harmful if swallowed.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P270 : Do not eat, drink or smoke when using this product.
P264 : Wash skin thoroughly after handling.
P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
Related Laws:
RTECS# LU5135000
Transport Information:
HS Number 2932209090
Application
Rofecoxib: A Selective Cyclooxygenase-2 (COX-2) Inhibitor

Rofecoxib is a non-steroidal anti-inflammatory drug (NSAID), and a selective cyclooxygenase-2 (COX-2) inhibitor. The mechanism of action is mainly by inhibition of the enzyme COX in the arachidonic acid metabolism pathway, resulting in reduced prostaglandin synthesis. In theory, a drug that selectively inhibited COX-2 might block inflammation, pain, and fever produced by prostaglandins while reducing the side effects (gastric erosions and ulcers) associated with inhibition of COX-1. For your reference, rofecoxib was withdrawn from the medicine market in 2004 after it was shown that long-term clinical use could increase the risk of heart attack and stroke. (The product is for research purpose only.)

References


PubMed Literature


TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Life Science
Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.